Safety Issues Clinical Trial
Official title:
A Prospective, 1-Arm, Open Label, Non-Randomized Study of the FERTI-LILY Conception Cup Device to Assess Label Comprehension, Device Usability and Safety in Women
NCT number | NCT05529160 |
Other study ID # | FCC-001 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 29, 2022 |
Est. completion date | September 21, 2022 |
Verified date | September 2022 |
Source | Rosesta Medical BV |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study is a prospective, 1-arm, open label, nonrandomized, single center study designed to evaluate label comprehension, device usability and safety of the FERTI·LILY Conception Cup. The primary safety endpoint will be an assessment of reported adverse events. Subjects will be screened -10 (±3) days prior to the baseline visit. At baseline, 15-20 subjects meeting the inclusion/exclusion criteria will be provided with a FERTI·LILY Conception Cup device and instructions for using the device. Subjects will participate in a label comprehension protocol that includes the physician confirmation that they have adequate comprehension to enroll. If not, a screen failure form is completed. Subjects will agree to try and use the device within 2 weeks of disposition therefore at baseline a two-week visit is scheduled. In the event they do not use the device within the two-week period the follow up visit can be rescheduled based on the visit window of +14 days. If it is not used within 4 weeks, the PI will have the subject return to the site to authorize another two-week period that will be captured as unscheduled follow up visit. The subject should complete the Device Experience Survey after each device use. The Device Experience Survey will be returned at this time, and adverse events will be assessed.
Status | Completed |
Enrollment | 18 |
Est. completion date | September 21, 2022 |
Est. primary completion date | September 20, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject is a female volunteer, age = 18 years. - Subject is willing and able to provide written informed consent for study participation. - Subject agrees to use the FCC device as directed. - Subject agrees to complete all study-related assessments. - Subject agrees to try to use the cup within two weeks of disposition. - PI confirms that the subject had the adequate label comprehension to enroll in the study. Exclusion Criteria: - Subject has a medical condition or other factor that, in the opinion of the investigator, would contraindicate participation in the study. - Subject has active bacterial vaginosis infection or vaginismus. - Subject has an abnormal clinically significant Pap Smear diagnosis. - Subject has a history of endometriosis. - Subject has any contraindications with the Instructions for Use. - Subject has an allergy to silicone. - Subject is pregnant or lactating. |
Country | Name | City | State |
---|---|---|---|
United States | Boca Raton Obstetrics and Gynecology | Boca Raton | Florida |
Lead Sponsor | Collaborator |
---|---|
Rosesta Medical BV |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of Device | Occurrence of device-related adverse events. | 6 weeks | |
Secondary | Label Comprehension Assessment Protocol | PI using questions and answers to assess comprehension and confirms subject can specify location and use of cup in vaginal model. | 6 weeks | |
Secondary | Device Usability | After use reported by subject: ease of use, user compliance, overall satisfaction, comfort, size of device. | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04485481 -
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT03473236 -
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
|
Phase 1 | |
Not yet recruiting |
NCT03683953 -
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells
|
Phase 1 | |
Recruiting |
NCT05546567 -
NOPARK Open Label Extension Study
|
N/A | |
Recruiting |
NCT05413226 -
Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility
|
N/A | |
Recruiting |
NCT05112159 -
Study of IPG1094 in Healthy Participants
|
Phase 1 | |
Completed |
NCT04689035 -
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144
|
Phase 1 | |
Completed |
NCT04335045 -
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
|
Phase 1 | |
Completed |
NCT05037227 -
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
|
||
Recruiting |
NCT05517291 -
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
|
N/A | |
Enrolling by invitation |
NCT06446778 -
Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
|
||
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Completed |
NCT04188821 -
Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
|
N/A | |
Completed |
NCT03667430 -
Safety Evaluation of Porous Silica in Men
|
N/A | |
Completed |
NCT04499482 -
Safety and Tolerability of Soy Fiber
|
N/A | |
Completed |
NCT03141905 -
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05244161 -
A Quasi-experimental Evaluation of the Malezi Program in Tanzania
|
N/A | |
Recruiting |
NCT03791372 -
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
|
Phase 1 | |
Withdrawn |
NCT04759066 -
The HEALiX™ Intubated Patient (IP) Pilot Study
|
N/A |